恩度联合奈达铂治疗晚期食道癌临床评价  

Clinical Evaluation of Endostar Combined with Nedaplatin in the Treatment of Advanced Esophageal Cancer

作　　者：孟新源[1] 汤旭山[1] 李俊杰 MENG Xinyuan;TANG Xushan;LI Junjie(Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China 830000)

机构地区：[1]新疆医科大学附属肿瘤医院,新疆乌鲁木齐830000

出　　处：《中国药业》2022年第12期102-104,共3页China Pharmaceuticals

基　　金：新疆维吾尔自治区科技厅科技计划项目[201417105]。

摘　　要：目的探讨恩度(重组人血管内皮抑制素)联合奈达铂化学药物治疗(简称化疗)对晚期食道癌的临床疗效。方法选取医院2019年3月至2020年6月收治的晚期食道癌患者96例,按随机数字表法分为试验组和对照组,各48例。两组患者均予注射用奈达铂60 mg/m^(2)静脉滴注,对照组患者加用氟尿嘧啶注射液120 mg/m^(2)静脉滴注,试验组患者加用重组人血管内皮抑制素注射液15 mg静脉滴注。两组患者均连续治疗2个疗程,并随访1年。结果试验组总有效率为91.67%,显著高于对照组的79.17%(P<0.05)。与对照组比较,试验组患者治疗后的γ-干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素6、转化生长因子-β_(1)(TGF-β_(1))及胰岛素样生长因子(IGF-1)水平显著降低(P<0.05)。1年后随访,试验组患者的生存率、卡氏生活质量(KPS)评分显著高于对照组(P<0.05);试验组和对照组的不良反应发生率相当(12.50%比14.58%,P>0.05)。结论恩度联合奈达铂治疗晚期食道癌能改善患者血清因子水平,提高1年生存率。Objective To investigate the clinical efficacy of Recombinant Human Endostation Injection(Endostar)combined with nedaplatin chemotherapy in the treatment of advanced esophageal cancer.Methods Ninety-six patients with advanced esophageal cancer admitted to the hospital from March 2019 to June 2020 were selected and divided into the test group and the control group according to the random number table method,with 48 cases in each group.The patients in the two groups were given the intravenous drip of Nedaplatin for Injection(60 mg/m^(2)),on this basis,patients in the control group were given the intravenous drip of Fluorouracil Injection(120 mg/m^(2)),and patients in the test group were given intravenous drip of Recombinant Human Endostatin Injection(Endostar,15 mg).Both groups were treated for two consecutive courses of treatment and followed up for one year.Results The total effective rate in the test group was 91.67%,which was significantly higher than 79.17%in the control group(P<0.05).After treatment,the levels of interferon-γ(IFN-γ),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6),transforming growth factor-β1(TGF-β1)and insulin-like growth factor-1(IGF-1)in the test group were significantly lower than those in the control group(P<0.05).After one year of follow-up,the survival rate and KPS score in the test group were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions in the test group was similar to that in the control group(12.50%vs.14.58%,P>0.05).Conclusion Endostar combined with nedaplatin can improve the level of serum factors and 1-year survival rate in patients with advanced esophageal cancer.

关 键 词：恩度 奈达铂 联合化疗 晚期食道癌 血清因子 1年生存率 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]